Brookline Capital Management Raises Kymera Therapeutics EPS Forecast

Summary

Brookline Capital Management’s stock research analyst has raised their EPS estimate for Kymera Therapeutics for Q3 2025 from ($1.03) to ($0.92). The full-year consensus estimate is ($2.79) per share. Other analysts also upgraded their ratings and target prices, with an average target price of $59.11. Kymera Therapeutics’ stock opened at $43.43, with a market cap of $2.83 billion. The company reported a 114.6% year-over-year revenue increase in the recent quarterly earnings report.Market Beat

Impact Analysis

The event is at the company level as it pertains specifically to Kymera Therapeutics. The upward revision of EPS estimates by Brookline Capital Management signifies positive expectations for the company’s financial performance, which can enhance investor confidence and potentially lead to stock price appreciation. Kymera Therapeutics’ significant revenue growth of 114.6% year-over-year supports this optimistic view, further validated by multiple analysts upgrading their ratings and target prices, indicating broad market support.Market Beat The acquisition of new holdings by GF Fund Management Co. Ltd. and increased stakes by other firms such as Tower Research Capital LLC and Millennium Management LLC suggests growing institutional investor interest and confidence in Kymera Therapeutics’ growth prospects.Market Beat+ 3 First-order effects include a likely increase in stock demand, potentially driving prices up. Second-order effects may involve improved market perception of the company’s strategic direction and operational execution, possibly attracting more long-term investors. Investment opportunities include considering Kymera Therapeutics stocks for their potential upside based on these improved earnings prospects and market sentiment shifts.